Hospital
MCHS Hospitals INC
MCHS Hospitals INC was paid $6.40M by Medicaid between Aug 2020 and Dec 2024, across 264 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 12% of everything it billed.
33Billing provider infoMCHS HOSPITALS INC
WESTON, WI 54476
WESTON, WI 54476
33aNPI1902437650assigned 01/31/2020
33bProvider typeGeneral Acute Care Hospital
28Total paid$6.40M
24GClaims308,480
24DCodes billed264
24AFirst – last monthAug 2020 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Wisconsin
Rank by total paid#21 of 60
Median peer was paid$2.90M
This provider vs. median2.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MUNSON, JOLYN controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 12,402 | $234K | |
| 2021 | 59,477 | $1.20M | |
| 2022 | 78,790 | $1.52M | |
| 2023 | 85,123 | $1.81M | |
| 2024incomplete | 72,688 | $1.63M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 12% | 12,518 | 10,962 | $798K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 12% | 12,440 | 10,757 | $760K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.1% | 10,118 | 8,322 | $581K |
| 96361 | Intravenous infusion, hydration; each additional hour | 8.2% | 4,555 | 3,014 | $526K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 5.9% | 7,343 | 5,845 | $378K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.3% | 2,701 | 2,351 | $148K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.3% | 2,498 | 1,775 | $147K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 2.2% | 2,307 | 1,985 | $143K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.0% | 3,027 | 2,485 | $131K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 2.0% | 2,304 | 2,162 | $129K |
| 80053 | Comprehensive metabolic panel | 1.9% | 10,718 | 8,159 | $122K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 1.8% | 1,960 | 1,834 | $113K |
252 more codes
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.6% | 1,552 | $101K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.5% | 1,919 | $95K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.4% | 2,317 | $93K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.3% | 1,282 | $82K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.3% | 1,039 | $81K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.3% | 1,919 | $80K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 13,687 | $80K |
| 99215 | Doctor's office visit, returning patient (complex) | 1.2% | 1,303 | $76K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.1% | 1,832 | $70K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.0% | 1,409 | $64K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 1,166 | $63K |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 984 | $62K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,104 | $59K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,006 | $55K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 791 | $53K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,627 | $48K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,612 | $47K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 572 | $46K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,021 | $42K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 838 | $40K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 7,333 | $40K |
| 90670 | <1% | 978 | $36K | |
| 84484 | <1% | 3,515 | $33K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 497 | $29K |
| 80061 | Lipid panel | <1% | 2,027 | $29K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 333 | $28K |
| 81001 | <1% | 7,425 | $27K | |
| 90674 | <1% | 1,741 | $27K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 938 | $26K |
| 87634 | <1% | 572 | $26K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,425 | $25K |
| 83735 | <1% | 5,410 | $23K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 603 | $23K |
| 81025 | <1% | 2,307 | $23K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,270 | $22K |
| 99243 | <1% | 341 | $21K | |
| 82728 | <1% | 1,360 | $20K | |
| 83880 | <1% | 708 | $20K | |
| 84145 | <1% | 844 | $19K | |
| 90680 | <1% | 932 | $18K | |
| 85610 | <1% | 2,464 | $18K | |
| 83690 | <1% | 3,507 | $17K | |
| 93296 | <1% | 610 | $17K | |
| 85027 | <1% | 2,301 | $16K | |
| 84702 | <1% | 493 | $15K | |
| 87186 | <1% | 835 | $14K | |
| 90633 | <1% | 566 | $14K | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 585 | $14K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 843 | $14K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 883 | $13K |
| 83605 | <1% | 1,349 | $13K | |
| 82962 | <1% | 2,845 | $12K | |
| 86140 | <1% | 3,055 | $12K | |
| 80306 | <1% | 658 | $12K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 212 | $11K |
| 11721 | <1% | 251 | $10K | |
| 90715 | <1% | 825 | $9K | |
| 90651 | <1% | 265 | $9K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 133 | $9K |
| 80050 | General health panel | <1% | 1,937 | $8K |
| 86803 | <1% | 596 | $8K | |
| 59025 | Fetal non-stress test | <1% | 114 | $8K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,409 | $8K |
| 0001A | <1% | 569 | $8K | |
| 0002A | <1% | 498 | $7K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 52 | $7K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 6,222 | $7K |
| 88142 | <1% | 425 | $7K | |
| 81514 | <1% | 50 | $6K | |
| 90619 | <1% | 179 | $6K | |
| 82077 | <1% | 699 | $6K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 81 | $6K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 94 | $6K |
| 93298 | <1% | 172 | $6K | |
| 87081 | <1% | 260 | $6K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 960 | $5K |
| 85379 | <1% | 716 | $5K | |
| 96367 | <1% | 86 | $5K | |
| 74018 | <1% | 646 | $5K | |
| 93976 | <1% | 180 | $5K | |
| 84439 | <1% | 671 | $5K | |
| 85730 | <1% | 1,153 | $5K | |
| 86850 | <1% | 1,293 | $5K | |
| 90686 | <1% | 550 | $5K | |
| 83550 | <1% | 722 | $5K | |
| 86780 | <1% | 447 | $4K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 109 | $4K |
| 87340 | <1% | 549 | $4K | |
| 90698 | <1% | 496 | $4K | |
| 81513 | <1% | 56 | $4K | |
| 97597 | <1% | 53 | $4K | |
| 73630 | <1% | 1,101 | $4K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 97 | $4K |
| 87653 | <1% | 75 | $4K | |
| 86703 | <1% | 306 | $3K | |
| 84703 | <1% | 439 | $3K | |
| 93297 | <1% | 169 | $3K | |
| 85652 | <1% | 1,663 | $3K | |
| 83540 | <1% | 684 | $3K | |
| 82784 | <1% | 330 | $3K | |
| 83655 | <1% | 158 | $3K | |
| 82950 | <1% | 231 | $3K | |
| 86762 | <1% | 143 | $3K | |
| 85018 | <1% | 648 | $3K | |
| 86900 | <1% | 1,216 | $3K | |
| 87040 | <1% | 385 | $2K | |
| 96376 | <1% | 2,116 | $2K | |
| 90716 | <1% | 75 | $2K | |
| 73562 | <1% | 481 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 982 | $2K |
| G0378 | Hospital observation service, per hour | <1% | 848 | $2K |
| 86901 | <1% | 1,215 | $2K | |
| 0012A | <1% | 119 | $2K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 82 | $2K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 41 | $2K |
| 82570 | <1% | 492 | $2K | |
| 76801 | <1% | 47 | $2K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 97 | $2K |
| 72100 | <1% | 192 | $2K | |
| 87077 | <1% | 259 | $2K | |
| 87070 | <1% | 150 | $2K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 41 | $2K |
| 86364 | <1% | 192 | $2K | |
| 90661 | <1% | 228 | $2K | |
| 96415 | <1% | 18 | $2K | |
| 82607 | <1% | 126 | $2K | |
| 90696 | <1% | 88 | $2K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 84 | $1K |
| 94060 | <1% | 46 | $1K | |
| 87481 | <1% | 56 | $1K | |
| 0011A | <1% | 129 | $1K | |
| 90734 | <1% | 50 | $1K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 28 | $1K |
| 99205 | Prolong outpt/office vis | <1% | 15 | $1K |
| G0008 | Administration of influenza virus vaccine | <1% | 753 | $1K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,420 | $1K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,109 | $1K |
| 84450 | <1% | 332 | $1K | |
| 99245 | <1% | 30 | $1K | |
| 83970 | <1% | 52 | $1K | |
| 0240U | <1% | 47 | $1K | |
| 80051 | <1% | 233 | $1K | |
| 82947 | <1% | 295 | $1K | |
| 0004A | <1% | 26 | $968.23 | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 73 | $929.58 |
| 84460 | <1% | 224 | $926.50 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 19,487 | $919.04 |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 14 | $910.90 |
| 20610 | <1% | 12 | $895.30 | |
| 76830 | Ultrasound, transvaginal | <1% | 40 | $884.45 |
| 86618 | <1% | 45 | $865.58 | |
| 90677 | <1% | 336 | $850.58 | |
| 82565 | <1% | 263 | $830.64 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 35 | $774.50 |
| 81003 | <1% | 214 | $769.85 | |
| 73610 | <1% | 397 | $750.73 | |
| 90697 | <1% | 538 | $709.22 | |
| 87075 | <1% | 35 | $694.01 | |
| 90744 | <1% | 123 | $691.67 | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 16 | $636.60 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 779 | $621.75 |
| 82043 | <1% | 170 | $619.55 | |
| 84520 | <1% | 233 | $580.10 | |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | <1% | 141 | $577.46 |
| 88720 | <1% | 19 | $546.82 | |
| 82040 | <1% | 170 | $542.70 | |
| 84075 | <1% | 142 | $492.68 | |
| 70355 | <1% | 63 | $483.32 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 46 | $460.78 |
| 36591 | <1% | 417 | $455.79 | |
| 90656 | <1% | 66 | $440.39 | |
| 87205 | <1% | 149 | $404.90 | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 12 | $364.24 |
| 90710 | <1% | 95 | $333.98 | |
| 84156 | <1% | 148 | $325.61 | |
| 0031A | <1% | 14 | $311.98 | |
| 90480 | <1% | 12 | $270.55 | |
| 90707 | <1% | 73 | $246.98 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 16 | $199.04 |
| 83001 | <1% | 13 | $192.00 | |
| 74019 | <1% | 121 | $188.30 | |
| 80069 | <1% | 49 | $162.27 | |
| 86038 | <1% | 16 | $138.51 | |
| 36592 | <1% | 4,291 | $108.02 | |
| 73502 | <1% | 12 | $102.96 | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 188 | $77.34 |
| 76937 | <1% | 18 | $71.18 | |
| 82550 | <1% | 18 | $60.57 | |
| 85007 | <1% | 18 | $44.28 | |
| 87210 | <1% | 15 | $42.00 | |
| 73030 | <1% | 67 | $37.22 | |
| 0124A | <1% | 31 | $37.17 | |
| 51798 | <1% | 59 | $35.78 | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 37 | $31.17 |
| 87088 | <1% | 15 | $25.08 | |
| 94664 | <1% | 13 | $18.23 | |
| 0072A | <1% | 40 | $12.39 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 27 | $6.19 |
| J2704 | Injection, propofol, 10 mg | <1% | 1,703 | $4.34 |
| J3490 | Unclassified drugs | <1% | 2,275 | $2.48 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 2,927 | $1.03 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,450 | $0.82 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,984 | $0.69 |
| J1815 | Injection, insulin, per 5 units | <1% | 18 | $0.23 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,463 | $0.14 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,222 | $0.07 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 229 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 39 | $0.00 |
| 73130 | 0% | 33 | $0.00 | |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 327 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 1,197 | $0.00 |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | 0% | 26 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 313 | $0.00 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 738 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 226 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 1,781 | $0.00 |
| 73110 | 0% | 16 | $0.00 | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 0% | 197 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 177 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 19 | $0.00 |
| 99152 | 0% | 21 | $0.00 | |
| 0071A | 0% | 13 | $0.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 27 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 16 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 50 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 18 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 21 | $0.00 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 0% | 85 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 1,713 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 1,750 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 64 | $0.00 |
| C1769 | Guide wire | 0% | 307 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 347 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 2,194 | $0.00 |
| 3044F | 0% | 49 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 937 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 2,534 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 277 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 52 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 275 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 2,850 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 161 | $0.00 |
| A9270 | Non-covered item or service | 0% | 1,212 | $0.00 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 0% | 144 | $0.00 |
| J3535 | Drug administered through a metered dose inhaler | 0% | 95 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 16 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 18 | $0.00 |
| G0009 | Administration of pneumococcal vaccine | 0% | 34 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 94 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 37 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 31 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 22 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMUNSON, JOLYN (VP REVENUE CYCLE OPERATIONS)
Parent organizationMARSHFEILD CLINIC HEALTH SYSTEM INC
| Provider | Location | Paid |
|---|---|---|
| MCHS Hospitals INC | Marshfield, WI | $45.31M |
| Marshfield Clinic INC | Marshfield, WI | $19.61M |
| MCHS Hospitals INC | Eau Claire, WI | $12.41M |
| MCHS Hospitals INC | Marshfield, WI | $11.82M |
| Beaver Dam Community Hospitals INC | Beaver Dam, WI | $10.58M |
| Dickinson County Healthcare System | Iron Mountain, MI | $10.23M |
| MCHS Hospitals INC | Ladysmith, WI | $7.36M |
| MCHS Hospitals INC | Eau Claire, WI | $4.14M |
| MCHS Hospitals INC | Minocqua, WI | $2.90M |
| Dickinson County Healthcare System | Iron Mountain, MI | $2.44M |
| Dickinson County Healthcare System | Iron Mountain, MI | $2.29M |
| MCHS Hospitals INC | Wausau, WI | $1.84M |
| MCHS Hospitals INC | Weston, WI | $1.22M |
| MCHS Hospitals INC | Minocqua, WI | $1.16M |
| MCHS Hospitals INC | Marshfield, WI | $988K |
| MCHS Hospitals INC | Ladysmith, WI | $867K |
| Beaver Dam Community Hospitals INC | Beaver Dam, WI | $847K |
| Dickinson County Healthcare System | Iron Mountain, MI | $648K |
| MCHS Hospitals INC | Marshfield, WI | $563K |
| MCHS Hospitals INC | Minocqua, WI | $338K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.